Suppr超能文献

质子泵抑制剂加速内皮细胞衰老。

Proton Pump Inhibitors Accelerate Endothelial Senescence.

作者信息

Yepuri Gautham, Sukhovershin Roman, Nazari-Shafti Timo Z, Petrascheck Michael, Ghebre Yohannes T, Cooke John P

机构信息

From the Department of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, TX (G.Y., R.S., T.Z.N-.S., J.P.C.); Department of Chemical Physiology, Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA (M.P.); and Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Houston, TX (Y.T.G.).

出版信息

Circ Res. 2016 Jun 10;118(12):e36-42. doi: 10.1161/CIRCRESAHA.116.308807. Epub 2016 May 10.

Abstract

RATIONALE

Proton pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for long-term use without medical supervision. Recent reports suggest that PPI use is associated with cardiovascular, renal, and neurological morbidity.

OBJECTIVE

To study the long-term effect of PPIs on endothelial dysfunction and senescence and investigate the mechanism involved in PPI-induced vascular dysfunction.

METHODS AND RESULTS

Chronic exposure to PPIs impaired endothelial function and accelerated human endothelial senescence by reducing telomere length.

CONCLUSIONS

Our data may provide a unifying mechanism for the association of PPI use with increased risk of cardiovascular, renal, and neurological morbidity and mortality.

摘要

理论依据

质子泵抑制剂(PPIs)是治疗胃食管反流的常用药物,目前无需医疗监督即可长期使用。最近的报告表明,使用PPIs与心血管、肾脏和神经疾病有关。

目的

研究PPIs对内皮功能障碍和衰老的长期影响,并探讨PPIs诱导血管功能障碍的机制。

方法与结果

长期接触PPIs会损害内皮功能,并通过缩短端粒长度加速人内皮细胞衰老。

结论

我们的数据可能为使用PPIs与心血管、肾脏和神经疾病及死亡风险增加之间的关联提供一个统一的机制。

相似文献

1
Proton Pump Inhibitors Accelerate Endothelial Senescence.
Circ Res. 2016 Jun 10;118(12):e36-42. doi: 10.1161/CIRCRESAHA.116.308807. Epub 2016 May 10.
3
Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis.
Therapie. 2018 May-Jun;73(3):273-281. doi: 10.1016/j.therap.2017.08.003. Epub 2017 Oct 14.
4
Nissen fundoplication proton pump inhibitors for laryngopharyngeal reflux based on pH-monitoring and symptom-scale.
World J Gastroenterol. 2017 May 21;23(19):3546-3555. doi: 10.3748/wjg.v23.i19.3546.
6
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Curr Gastroenterol Rep. 2017 Sep;19(9):46. doi: 10.1007/s11894-017-0586-5.
7
Proton Pump Inhibitors: Review of Emerging Concerns.
Mayo Clin Proc. 2018 Feb;93(2):240-246. doi: 10.1016/j.mayocp.2017.10.022.
8
10
Practical considerations in the management of proton-pump inhibitors.
Rev Esp Enferm Dig. 2016 Mar;108(3):145-53. doi: 10.17235/reed.2015.3812/2015.

引用本文的文献

2
Can proton pump inhibitors increase the risk of sudden unexpected death in Parkinson's disease (SUDPAR)?
Clinics (Sao Paulo). 2025 Jul 31;80:100721. doi: 10.1016/j.clinsp.2025.100721.
3
Gastroesophageal reflux disease and osteoporosis: A bidirectional Mendelian randomization study.
Medicine (Baltimore). 2025 Apr 4;104(14):e42083. doi: 10.1097/MD.0000000000042083.
4
The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence.
Front Aging. 2024 Dec 17;5:1466281. doi: 10.3389/fragi.2024.1466281. eCollection 2024.
5
Current study of pathogenetic mechanisms and therapeutics of chronic atrophic gastritis: a comprehensive review.
Front Cell Dev Biol. 2024 Dec 10;12:1513426. doi: 10.3389/fcell.2024.1513426. eCollection 2024.
6
Proton pump inhibitor use and risk of stroke: A systematic review and meta-analysis.
Pak J Med Sci. 2024 Nov;40(10):2432-2440. doi: 10.12669/pjms.40.10.10409.
7
Proton pump inhibitors and cardiovascular risk: a critical review.
Future Cardiol. 2024;20(14):779-794. doi: 10.1080/14796678.2024.2412910. Epub 2024 Oct 28.
8
Frataxin Loss Promotes Angiotensin II-Induced Endothelial-to-Mesenchymal Transition.
J Am Heart Assoc. 2024 Aug 6;13(15):e034316. doi: 10.1161/JAHA.124.034316. Epub 2024 Jul 18.
9
Omeprazole and Risk of Hypertension: Analysis of Existing Literature and the WHO Global Pharmacovigilance Database.
Drugs Real World Outcomes. 2024 Dec;11(4):735-744. doi: 10.1007/s40801-024-00441-2. Epub 2024 Jun 22.

本文引用的文献

2
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193.
3
Age intrinsic loss of telomere protection via TRF1 reduction in endothelial cells.
Biochim Biophys Acta. 2016 Feb;1863(2):360-7. doi: 10.1016/j.bbamcr.2015.11.034. Epub 2015 Dec 1.
4
Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold.
Kidney Res Clin Pract. 2015 Jun;34(2):76-82. doi: 10.1016/j.krcp.2015.05.003. Epub 2015 Jun 4.
6
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.
PLoS One. 2015 Jun 10;10(6):e0124653. doi: 10.1371/journal.pone.0124653. eCollection 2015.
7
Protein-protein interactions within the ensemble, eukaryotic V-ATPase, and its concerted interactions with cellular machineries.
Prog Biophys Mol Biol. 2015 Oct;119(1):84-93. doi: 10.1016/j.pbiomolbio.2015.05.003. Epub 2015 May 29.
8
Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
Vasc Med. 2015 Aug;20(4):309-16. doi: 10.1177/1358863X14568444. Epub 2015 Apr 2.
9
Molecular mechanisms of autophagy in the cardiovascular system.
Circ Res. 2015 Jan 30;116(3):456-67. doi: 10.1161/CIRCRESAHA.114.303788.
10
Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells.
FASEB J. 2015 May;29(5):1930-9. doi: 10.1096/fj.14-259531. Epub 2015 Jan 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验